Enzalutamide and abiraterone in the treatment of patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
Authors:
S. Al-Samsam 1; J. Bartoš 1; V. Šámal 2; J. Dvořák 3; H. Kolářová 4; I. Richter 1,3,5
Authors‘ workplace:
Onkologické oddělení, Krajská nemocnice Liberec, a. s.
1; Urologické oddělení, Krajská nemocnice Liberec, a. s.
2; Onkologická klinika 1. LF UK a FTN Praha
3; MATSTAT Praha
4; Fakulta zdravotnických studií, Technická univerzita Liberec
5
Published in:
Klin Onkol 2023; 37(4): 300-306
Category:
Original Articles
Overview
Background: The evaluation of treatment outcomes and toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC) treated by enzalutamide or abiraterone after previous docetaxel.
Patients and methods: We analyzed 66 patients with mCRPC treated by enzalutamide (55 patients) or abiraterone (11 patients) after previous therapy with docetaxel. The median follow-up was 31.2 months. Enzalutamide and abiraterone were administered in daily doses of 160 mg and 1,000 mg per day, respectively. The progression free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier analysis. The prognostic influence of the factors on OS was evaluated by regression analysis.
Results: The progression was observed in 55 (83%) patients, and mPFS was 12.1 (95% CI 7.7–16.4) months. In total, 43 patients died, and he median OS was 21.9 (95% CI 12.2–31.7) months. In the regression analysis, we observed statistical favorable influence of the following factors on OS: PSA decrease ≥ 50%, in patients with early decrease of prostatic specific antigen (PSA) ≥ 50% in 3 months after initiation of enzalutamide or abiraterone treatment, in patients with visceral metastatic sites, in patients treated with only one regimen of previous chemotherapy and in those without anemia. We observed the toxicity grades 3–4 in 45.5% and 36.3% patients treated with enzalutamide and abiraterone, respectively.
Conclusion: Our analysis demonstrated efficacy and good tolerance in patients with mCRPC treated with enzalutamide and abiraterone after previous docetaxel therapy.
Keywords:
Chemotherapy – metastases – targeted therapy – abiraterone – enzalutamide – androgen receptor – castration-resistant prostate cancer
Sources
1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. Brno: Masarykova univerzita 2005.
2. Mottet N, Bellmunt J, van den Bergh RCN et al. EAU Guidelines on prostate cancer – update April 2014. Arnhem: European Association of Urology 2014.
3. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502–1512. doi: 10.1056/NEJMoa040720.
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone plus prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513–1520. doi: 10.1056/ NEJMoa041318.
5. Rozsypalová A, Dvořák J, Richter I et al. Aktuální možnosti léčby metastazujícího kastračně rezistentního karcinomu prostaty. Onkol Revue 2018; 2: 36–38.
6. Richter I, Dvořák J, Bartoš J. Options of chemotherapy in the treatment of prostate cancer. Klin Onkol 2017; 30 (1): 28–33. doi: 10.14735/amko201728.
7. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostatae cancer progressing after docetaxel treatment: a randimised open-label trial. Lancet 2010; 376 (9747): 1147–1154. doi: 10.1016/S0140-67 36 (10) 61389-X.
8. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (3): 213–223. doi: 10.1056/NEJM- oa1213755.
9. Sartor AO. Progression of metastatic castrate-resistant prostatae cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 2011; 4: 18. doi: 10.1186/1756-8722-4-18.
10. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2003; 10 (1): 33–39. doi: 10.1038/nm972.
11. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer directed therapies targeting the androgen-receptor signaling axil. J Clin Oncol 2005; 23 (32): 8253–8261. doi: 10.1200/JCO.2005.03.4777.
12. Richter I, Dvořák J. Enzalutamid v léčbě metastatického kastračně rezistentního karcinomu prostaty. Onkologie 2019; 13 (4): 157–160. doi: 10.36290/xon.2019. 030.
13. Richter I, Dvořák J. Abirateron acetát. Praha: Farmakon Press 2017: 733–736.
14. Fizazi K, Sher HI, Molina A et al. Abiraterone acetae for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13 (10): 983–992. doi: 10.1016/S1470-2045 (12) 70379-0.
15. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187–1197. doi: 10.1056/ NEJMoa1207506.
16. Armstrong AJ, Tannock IF, de Wit R et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010; 46 (3): 517–525. doi: 10.1016/j.ejca.2009.11.007.
17. Halabi S, Armstrong AJ, Sartor O et al. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol 2013; 31 (31): 3944–3950. doi: 10.1200/JCO.2013.50. 3201.
18. Xu XS, Ryan CJ, Stuyckens K et al. Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients. Clin Cancer Res 2015; 21 (14): 3170–3177. doi: 10.1158/1078-0432.CCR-14-1549.
19. Conteduca V, Crabb SJ, Scarpi E et al. Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer. Mol Diagn Ther 2016; 20 (3): 255–263. doi: 10.1007/s40291-016-0196-1.
20. Richter I, Dvořák J, Bartoš J. Docetaxel-cabazitaxel-enzalutamide versus docetaxel-enzalutamide in patients with metastatic castration-resistant prostate cancer. Klin Onkol 2017; 30 (4): 289–293. doi: 10.14735/amko2017289.
21. Richter I, Dvořák J, Hejzlarová V et al. Kabazitaxel v léčbě metastatického kastračně rezistentního karcinomu prostaty. Ces Urol 2016; 20 (3): 214–220.
22. Billis A, Quintal MM, Meirelles L et al. The value of the 2005 International Society of Urological Pathology (ISUP) modified Gleason grading system as a predictor of biochemical recurrence after radical prostatectomy. Int Urol Nephrol 2014; 46 (5): 935–940. doi: 10.1007/s11255-013-0579-8.
23. Buhmeida A, Pyrhonen S, Laato M et al. Prognostic factors in prostate cancer. Diagn Pathol 2006; 1: 4. doi: 10.1186/1746-1596-1-4.
24. Fizazi K, Flaig TW, Stöckle M et al. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol 2016; 27 (4): 699–705. doi: 10.1093/annonc/mdv545.
25. Azria D, Massard C, Tosi D et al. An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): predictive parameters of response. ASCO Meeting Abstr 2012; 30: 149.
26. Loriot Y, Massard C, Albiges L et al. Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity. J Clin Oncol 2012; 30 (5 Suppl): 213.
27. Di Stefano RF, Tucci M, Turco F et al. Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis 2021; 24 (3): 812–825. doi: 10.1038/s41391-021-00336-1.
28. Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia 2001; 42 (Suppl 3): 8–12. doi: 10.1046/j.1528-1157.2001.042suppl.3008.x.
29. Hussain MAhoj, Fizazi K, Saad F et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018; 378 (26): 2465–2474. doi: 10.1056/ NEJMoa1800536.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2023 Issue 4
Most read in this issue
- Enzalutamide and abiraterone in the treatment of patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
- Circulating free DNA and its potential in the diagnostics and therapy of malignant lymphoma
- How patients can help us be even better doctors – educational leaflet “Before I go to the doctor”
- News in the fifth edition of World Health Organization classification of testicular tumors